SYK Valuation Metrics
SYK Stock Price Metrics
SYK Dividend Metrics
SYK Growth Rate Metrics
SYK Discounted Cash Flow Metrics
| Fair Value Price | $340.18 |
| Margin of Safety | 9.53% |
SYK Revenue Metrics
SYK PE Ratio Metrics
| PE Ratio | 35.95 |
| PE Ratio Avg TTM | 45.95 |
| PE Ratio Avg 3Y | 43.57 |
| Current VS TTM Avg | -21.76% |
| Current VS 3Y Avg | -17.49% |
| Current VS 5Y Avg | -18.29% |
SYK PS Ratio Metrics
| PS Ratio | 4.75 |
| PS Ratio Avg TTM | 5.71 |
| PS Ratio Avg 3Y | 6.04 |
| Current VS TTM Avg | -16.84% |
| Current VS 3Y Avg | -21.35% |
| Current VS 5Y Avg | -18.73% |
SYK PB Ratio Metrics
| PB Ratio | 5.22 |
| PB Ratio Avg TTM | 6.38 |
| PB Ratio Avg 3Y | 6.71 |
| Current VS TTM Avg | -18.23% |
| Current VS 3Y Avg | -22.26% |
| Current VS 5Y Avg | -20.13% |
SYK Price to Free Cash Flow Ratio Metrics
| PFCF Ratio | 26.26 |
| PFCF Ratio Avg TTM | 34.13 |
| PFCF Ratio Avg 3Y | 41.28 |
| Current VS TTM Avg | -23.05% |
| Current VS 3Y Avg | -36.38% |
| Current VS 5Y Avg | -35.32% |
SYK Debt to Equity Ratio Metrics
| Debt/Equity Ratio | 0.73 |
| Debt/Equity Ratio Avg TTM | 0.71 |
| Debt/Equity Ratio Avg 3Y | 0.74 |
| Current VS TTM Avg | +3.55% |
| Current VS 3Y Avg | -1.02% |
| Current VS 5Y Avg | -10.98% |
SYK PEG Ratio Metrics
| PEG Ratio | 5.16 |
| PEG Ratio Avg TTM | - |
| PEG Ratio Avg 3Y | 2.81 |
| Current VS TTM Avg | - |
| Current VS 3Y Avg | +83.63% |
| Current VS 5Y Avg | +96.20% |
SYK FCF Yield
| FCF Yield | 3.81% |
| FCF Yield Avg TTM | 2.95% |
| FCF Yield Avg 3Y | 2.43% |
| Current VS TTM Avg | +29.36% |
| Current VS 3Y Avg | +56.91% |
| Current VS 5Y Avg | +51.50% |
SYK Earnings Yield
| Earnings Yield | 2.78% |
| Earnings Yield Avg TTM | 2.21% |
| Earnings Yield Avg 3Y | 2.33% |
| Current VS TTM Avg | +25.59% |
| Current VS 3Y Avg | +19.56% |
| Current VS 5Y Avg | +21.64% |
SYK EV/EBIT Ratio Metrics
| Ev/Ebit Ratio | 24.55 |
| Ev/Ebit Ratio Avg TTM | 28.21 |
| Ev/Ebit Ratio Avg 3Y | 30.74 |
| Current VS TTM Avg | -12.98% |
| Current VS 3Y Avg | -20.14% |
| Current VS 5Y Avg | -18.52% |
SYK EV/EBITDA Ratio Metrics
| Ev/Ebitda Ratio | 21.49 |
| Ev/Ebitda Ratio Avg TTM | 30.83 |
| Ev/Ebitda Ratio Avg 3Y | 30.96 |
| Current VS TTM Avg | -30.29% |
| Current VS 3Y Avg | -30.58% |
| Current VS 5Y Avg | -29.24% |
SYK EV/Assets Ratio Metrics
| Ev/Assets Ratio | 2.86 |
| Ev/Assets Ratio Avg TTM | 3.26 |
| Ev/Assets Ratio Avg 3Y | 3.43 |
| Current VS TTM Avg | -12.25% |
| Current VS 3Y Avg | -16.67% |
| Current VS 5Y Avg | -12.70% |
SYK EV/Sales Ratio Metrics
| Ev/Sales Ratio | 5.24 |
| Ev/Sales Ratio Avg TTM | 6.28 |
| Ev/Sales Ratio Avg 3Y | 6.61 |
| Current VS TTM Avg | -16.57% |
| Current VS 3Y Avg | -20.73% |
| Current VS 5Y Avg | -18.74% |
SYK Current Ratio Metrics
| Current Ratio | 1.89 |
| Current Ratio Avg TTM | 1.92 |
| Current Ratio Avg 3Y | 1.76 |
| Current VS TTM Avg | -1.56% |
| Current VS 3Y Avg | +7.23% |
| Current VS 5Y Avg | +1.43% |
SYK Quick Ratio Metrics
| Quick Ratio | 1.21 |
| Quick Ratio Avg TTM | 1.27 |
| Quick Ratio Avg 3Y | 1.13 |
| Current VS TTM Avg | -4.35% |
| Current VS 3Y Avg | +7.56% |
| Current VS 5Y Avg | +0.83% |
SYK ROIC Metrics
| ROIC | 8.53% |
| ROIC Avg 3Y | 10.34% |
| ROIC Avg 5Y | 10.08% |
| Current VS 3Y Avg | -17.48% |
| Current VS 5Y Avg | -15.35% |
| Current VS 10Y Avg | -19.23% |
SYK Return on Assets Metrics
| ROA | 6.78 |
| ROA Avg TTM | 6.88 |
| ROA Avg 3Y | 7.02 |
| Current VS TTM Avg | -1.38% |
| Current VS 3Y Avg | -3.38% |
| Current VS 5Y Avg | +5.69% |
SYK Return on Equity Metrics
| ROE | 14.48 |
| ROE Avg TTM | 14.50 |
| ROE Avg 3Y | 15.05 |
| Current VS TTM Avg | -0.10% |
| Current VS 3Y Avg | -3.79% |
| Current VS 5Y Avg | +1.24% |
SYK Net Profit Margin Metrics
| Net Profit Margin | 12.92% |
| Net Profit Margin Avg TTM | 13.09% |
| Net Profit Margin Avg 3Y | 13.60% |
| Current VS TTM Avg | -1.26% |
| Current VS 3Y Avg | -4.98% |
| Current VS 5Y Avg | +0.43% |
Last Updated: Wednesday, June 17, 2026
About Stryker Corporation
Stryker Corporation functions as a prominent medical technology enterprise, with its operations structured across two main divisions. The Orthopaedics and Spine segment specializes in providing implants for joint replacement procedures (including hips and knees), as well as solutions for trauma and extremities surgeries. This division also furnishes a comprehensive suite of spinal implant products, such as cervical, thoracolumbar, and interbody systems, utilized in addressing spinal injuries, deformities, and degenerative conditions. The MedSurg and Neurotechnology division offers an extensive array of products, encompassing advanced surgical equipment, surgical navigation systems, endoscopic and communication tools, patient handling devices, emergency medical apparatus, and critical care disposable items. This segment also deals in reprocessed and remanufactured medical devices, catering to various medical specialties. Furthermore, its neurotechnology offerings include devices for minimally invasive endovascular techniques, instruments for brain and open skull-based surgical interventions, and orthobiologic and biosurgery products like synthetic bone grafts and vertebral augmentation solutions. It also provides specialized minimally invasive products for treating acute ischemic and hemorrhagic strokes, alongside craniomaxillofacial implants, which include cranial, maxillofacial, and chest wall devices, in addition to dural substitutes and sealants. Stryker distributes its diverse portfolio to medical professionals, hospitals, and other healthcare institutions in approximately 75 countries, leveraging its network of company-owned subsidiaries, regional branches, and independent dealers and distributors. Established in 1941, Stryker Corporation is headquartered in Kalamazoo, Michigan.
- Sector
- Healthcare
- Industry
- Medical - Devices
- CEO
- Kevin A. Lobo